{
    "id": 105,
    "premise": "none",
    "hypothesis": "HER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
    "label": "entailment",
    "explanation": "Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "HER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
        "history explanation": [
            "0 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2- activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.",
            "1 iteration: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy.\nThe location of the HER2 V777L mutation in the tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain.",
            "2 iteration: Trastuzumab binds to the HER2 extracellular domain, which may result in no inhibitory effect on mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy due to its location in the intracellular domain, which is not targeted by trastuzumab.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain.",
            "3 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not inhibit mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain.\nHER2 V777L may cause resistance to antibody therapy due to its location in the intracellular domain, which is not targeted by trastuzumab.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain.",
            "4 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.",
            "5 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, and this location can lead to resistance to antibody therapy.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.",
            "6 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab. This specific location directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.",
            "7 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance.\nThe specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.",
            "8 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance.\nThe specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.\nThe HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy.",
            "9 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance.\nThe specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.\nThe HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy.",
            "10 iteration: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain.\nThe HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance.\nThe specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain.\nThe HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target.\nThe location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain.\nThe HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n(* Explanation 3 provides that HER2 V777L may cause resistance to antibody therapy. *)\\n(* We can use the logical relation Implies(C, D) to infer that HER2 V777L causes resistance to antibody therapy. *)\\nfrom explanation_2 and explanation_3 have \"Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z y\" sledgehammer', 'solving time': 103.76331424713135, 'proof tactics': [], 'code': 'theory clinical_105_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2Domain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  InhibitoryEffect :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Have :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2Domain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 ExtracellularDomain y \u2227 InhibitoryEffect z \u2227 Mutation y \u2227 IntracellularDomain y \u2227 Have e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Mutation x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy z \u2227 Cause e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab y \u2227 Mutation x \u2227 IntracellularDomain x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 ExtracellularDomain z \u2227 Mutation x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Trastuzumab, Mutation, and IntracellularDomain. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab y \u2227 Mutation x \u2227 IntracellularDomain x\" <ATP>\\n  (* Explanation 2 provides that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  (* Explanation 3 provides that HER2 V777L may cause resistance to antibody therapy. *)\\n  (* We can use the logical relation Implies(C, D) to infer that HER2 V777L causes resistance to antibody therapy. *)\\n  from explanation_2 and explanation_3 have \"Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z y\" <ATP>\\n  (* Explanation 1 provides that trastuzumab binds to the HER2 extracellular domain. *)\\n  (* We can use the logical relation Implies(A, B) to infer that trastuzumab has no inhibitory effect on the mutation in the intracellular domain. *)\\n  from explanation_1 have \"Bind e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 ExtracellularDomain z\" <ATP>\\n  (* Combining all the information, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: trastuzumab has no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain (from Explanatory Sentence 1)\\nC: HER2 V777L mutation is located in the tyrosine kinase domain (from Explanatory Sentence 2)\\nD: HER2 V777L causes resistance to antibody therapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, trastuzumab has no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L causes resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n(* This corresponds to logical proposition C. *)\\nfrom explanation_2 have \"\u2203y. HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\" sledgehammer', 'solving time': 104.26070976257324, 'proof tactics': [], 'code': 'theory clinical_105_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  InhibitoryEffect :: \"event \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 Mutation z \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 ExtracellularDomain y \u2227 InhibitoryEffect e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 IntracellularDomain z\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Mutation x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy z \u2227 Cause e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\"\\n\\n(* Explanation 4: The location of the HER2 V777L mutation in the tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. HER2V777L x \u2227 Mutation x \u2227 TyrosineKinaseDomain y \u2227 Resistance z \u2227 Trastuzumab w \u2227 Lead e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z w \u2227 Target e2 \u2227 Agent e2 w \u2227 Patient e2 y \u2227 ExtracellularDomain y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the known information, we have HER2V777L x and Trastuzumab z. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab z\" <ATP>\\n  \\n  (* Explanation 2 provides that HER2 V777L mutation is located in the tyrosine kinase domain. *)\\n  (* This corresponds to logical proposition C. *)\\n  from explanation_2 have \"\u2203y. HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 LocatedIn x y\" <ATP>\\n  \\n  (* Explanation 4 states that the location of the HER2 V777L mutation in the tyrosine kinase domain leads to resistance to trastuzumab, as trastuzumab targets the extracellular domain. *)\\n  (* This corresponds to logical proposition E and F. *)\\n  from explanation_4 have \"\u2203y z w e1 e2. HER2V777L x \u2227 TyrosineKinaseDomain y \u2227 Resistance z \u2227 Trastuzumab w \u2227 Lead e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z w \u2227 Target e2 \u2227 Agent e2 w \u2227 Patient e2 y \u2227 ExtracellularDomain y\" <ATP>\\n  \\n  (* Using the logical relation Implies(And(C, F), E), we can infer that the location of the HER2 V777L mutation in the tyrosine kinase domain leads to resistance to trastuzumab. *)\\n  (* Therefore, we can conclude that HER2 V777L may cause resistance to trastuzumab. *)\\n  then have \"\u2203y z e1 e2. Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: trastuzumab binds to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: trastuzumab has no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain (from Explanatory Sentence 1)\\nC: HER2 V777L mutation is located in the tyrosine kinase domain (from Explanatory Sentence 2)\\nD: HER2 V777L causes resistance to antibody therapy (from Explanatory Sentence 3)\\nE: location of the HER2 V777L mutation in the tyrosine kinase domain leads to resistance to trastuzumab (from Explanatory Sentence 4)\\nF: trastuzumab targets the extracellular domain (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(trastuzumab binds to the HER2 extracellular domain, trastuzumab has no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain)\\n--------\\nEquivalent(C, C)\\nTrue\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the tyrosine kinase domain, HER2 V777L causes resistance to antibody therapy)\\n--------\\nImplies(And(C, F), E)\\nImplies(C & F, location of the HER2 V777L mutation in the tyrosine kinase domain leads to resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that Trastuzumab binds to the HER2 extracellular domain, which may result in no inhibitory effect on mutations located in the intracellular kinase domain. *)\\n(* This corresponds to logical proposition A and B. *)\\nfrom explanation_1 have \"Trastuzumab y \u27f6 ExtracellularDomain z\" sledgehammer', 'solving time': 225.16735649108887, 'proof tactics': [], 'code': 'theory clinical_105_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Binds :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  NoInhibitoryEffect :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  IntracellularTyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Targeted :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Targets :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds to the HER2 extracellular domain, which may result in no inhibitory effect on mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Binds e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Result e2 \u2227 Agent e2 y \u2227 NoInhibitoryEffect z \u2227 Mutations z \u2227 IntracellularDomain z\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2200x. HER2V777L x \u27f6 IntracellularTyrosineKinaseDomain x\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy due to its location in the intracellular domain, which is not targeted by trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1. HER2V777L x \u2227 AntibodyTherapy y \u2227 Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 IntracellularDomain x \u2227 \u00ac(\u2203e2. Targeted e2 \u2227 Agent e2 y \u2227 Patient e2 x)\"\\n\\n(* Explanation 4: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 IntracellularTyrosineKinaseDomain x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Lead e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Targets e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 ExtracellularDomain y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Binds e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 ExtracellularDomain z \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Trastuzumab, and Resistance. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z\" <ATP>\\n  (* Explanation 2 provides that HER2V777L is located in the intracellular tyrosine kinase domain. *)\\n  (* This corresponds to logical proposition C. *)\\n  from explanation_2 have \"HER2V777L x \u27f6 IntracellularTyrosineKinaseDomain x\" <ATP>\\n  (* Since we have HER2V777L x, we can infer IntracellularTyrosineKinaseDomain x. *)\\n  then have \"IntracellularTyrosineKinaseDomain x\" <ATP>\\n  (* Explanation 4 provides that the location of HER2V777L in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab. *)\\n  (* This corresponds to logical relation Implies(C, F). *)\\n  from explanation_4 have \"HER2V777L x \u27f6 Resistance z\" <ATP>\\n  (* Since we have HER2V777L x, we can infer Resistance z. *)\\n  then have \"Resistance z\" <ATP>\\n  (* Explanation 1 provides that Trastuzumab binds to the HER2 extracellular domain, which may result in no inhibitory effect on mutations located in the intracellular kinase domain. *)\\n  (* This corresponds to logical proposition A and B. *)\\n  from explanation_1 have \"Trastuzumab y \u27f6 ExtracellularDomain z\" <ATP>\\n  (* Since we have Trastuzumab y, we can infer ExtracellularDomain z. *)\\n  then have \"ExtracellularDomain z\" <ATP>\\n  (* We have all the components to construct the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: No inhibitory effect on mutations located in the intracellular kinase domain (from Explanatory Sentence 1)\\nC: HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: HER2 V777L may cause resistance to antibody therapy (from Explanatory Sentence 3)\\nE: Trastuzumab targets the extracellular domain (from Explanatory Sentence 4)\\nF: Resistance to trastuzumab (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Trastuzumab binds to the HER2 extracellular domain, No inhibitory effect on mutations located in the intracellular kinase domain)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation is located in the intracellular tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\nImplies(C, F)\\nImplies(HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(E, F)\\nImplies(Trastuzumab targets the extracellular domain, Resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* We have logical relations Implies(C, E) and Implies(F, E). *)\\n(* C: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\n(* E: The location of the HER2 V777L mutation can lead to resistance to trastuzumab. *)\\n(* F: Trastuzumab targets the extracellular domain. *)\\n(* From explanation_2, we know HER2V777L x implies C. *)\\nfrom explanation_2 have \"HER2V777L x \u27f6 (\u2203y. IntracellularTyrosineKinaseDomain y \u2227 LocatedIn x y)\" sledgehammer', 'solving time': 103.2348039150238, 'proof tactics': [], 'code': 'theory clinical_105_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  IntracellularTyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not inhibit mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Inhibit e2 \u2227 \u00acAgent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 LocatedIn x y\"\\n\\n(* Explanation 3: HER2 V777L may cause resistance to antibody therapy due to its location in the intracellular domain, which is not targeted by trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy z \u2227 IntracellularDomain w \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Location x w \u2227 Target e2 \u2227 \u00acAgent e2 w \u2227 Patient e2 x \u2227 By e2 y\"\\n\\n(* Explanation 4: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Resistance z \u2227 Trastuzumab w \u2227 Location x y \u2227 Lead e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 To z w \u2227 Target e2 \u2227 Agent e2 w \u2227 Patient e2 y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Trastuzumab, and Resistance. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z\" <ATP>\\n  (* We have logical relations Implies(C, E) and Implies(F, E). *)\\n  (* C: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\n  (* E: The location of the HER2 V777L mutation can lead to resistance to trastuzumab. *)\\n  (* F: Trastuzumab targets the extracellular domain. *)\\n  (* From explanation_2, we know HER2V777L x implies C. *)\\n  from explanation_2 have \"HER2V777L x \u27f6 (\u2203y. IntracellularTyrosineKinaseDomain y \u2227 LocatedIn x y)\" <ATP>\\n  (* From explanation_4, we know E implies A. *)\\n  from explanation_4 have \"HER2V777L x \u27f6 (\u2203y z w e1 e2. IntracellularTyrosineKinaseDomain y \u2227 Resistance z \u2227 Trastuzumab w \u2227 Location x y \u2227 Lead e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 To z w \u2227 Target e2 \u2227 Agent e2 w \u2227 Patient e2 y)\" <ATP>\\n  (* From explanation_1, we know A: Trastuzumab binds specifically to the HER2 extracellular domain. *)\\n  from explanation_1 have \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Inhibit e2 \u2227 \u00acAgent e2 x \u2227 Patient e2 z\" <ATP>\\n  (* Using the logical relations and derived implications, we can infer the hypothesis. *)\\n  then have \"\u2203x y z e1 e2. HER2V777L x \u2227 Trastuzumab y \u2227 Resistance z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 To z y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Binding does not inhibit mutations located in the intracellular kinase domain (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: HER2 V777L may cause resistance to antibody therapy (from Explanatory Sentence 3)\\nE: The location of the HER2 V777L mutation can lead to resistance to trastuzumab (from Explanatory Sentence 4)\\nF: Trastuzumab targets the extracellular domain (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, HER2 V777L may cause resistance to antibody therapy)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The location of the HER2 V777L mutation can lead to resistance to trastuzumab)\\n--------\\nImplies(F, E)\\nImplies(Trastuzumab targets the extracellular domain, The location of the HER2 V777L mutation can lead to resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Not(The location of the HER2 V777L mutation can lead to resistance to trastuzumab))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(HER2 V777L may cause resistance to antibody therapy))\\n--------\\nImplies(Not(F), B)\\nImplies(Not(Trastuzumab targets the extracellular domain), Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(B), Not(F))\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Not(Trastuzumab targets the extracellular domain))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(HER2 V777L may cause resistance to antibody therapy, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(B, A)\\nImplies(Binding does not inhibit mutations located in the intracellular kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Binding does not inhibit mutations located in the intracellular kinase domain))\\n--------\\nImplies(E, A)\\nImplies(The location of the HER2 V777L mutation can lead to resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The location of the HER2 V777L mutation can lead to resistance to trastuzumab))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(The location of the HER2 V777L mutation can lead to resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), The location of the HER2 V777L mutation can lead to resistance to trastuzumab)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(F, A)\\nImplies(Trastuzumab targets the extracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(F))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab targets the extracellular domain))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(HER2 V777L may cause resistance to antibody therapy, Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), HER2 V777L may cause resistance to antibody therapy)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Not(HER2 V777L may cause resistance to antibody therapy))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(HER2 V777L may cause resistance to antibody therapy), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(The location of the HER2 V777L mutation can lead to resistance to trastuzumab, Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(B), F)\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(The location of the HER2 V777L mutation can lead to resistance to trastuzumab), Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The location of the HER2 V777L mutation can lead to resistance to trastuzumab)\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), HER2 V777L may cause resistance to antibody therapy)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(F, B)\\nImplies(Trastuzumab targets the extracellular domain, Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(F), A)\\nImplies(Not(Trastuzumab targets the extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Binding does not inhibit mutations located in the intracellular kinase domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(HER2 V777L may cause resistance to antibody therapy), Binding does not inhibit mutations located in the intracellular kinase domain)\\n--------\\nImplies(Not(A), F)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab targets the extracellular domain)\\n--------\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Using the logical relation Implies(C, E), we know that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it may cause resistance to antibody therapy. *)\\n(* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\nfrom explanation_2 have \"HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 LocatedIn x y \u2227 Trastuzumab z \u2227 \u00acTargetedBy x z\" sledgehammer', 'solving time': 103.27667260169983, 'proof tactics': [], 'code': 'theory clinical_105_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  IntracellularTyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  LocatedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  TargetedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Affect e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 \u00acAffect e2\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 LocatedIn x y \u2227 Trastuzumab z \u2227 \u00acTargetedBy x z\"\\n\\n(* Explanation 3: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1. HER2V777L x \u2227 Mutation x \u2227 Resistance y \u2227 AntibodyTherapy z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 IntracellularDomain x \u2227 LocatedIn x x \u2227 Trastuzumab z \u2227 \u00acTargetedBy x z\"\\n\\n(* Explanation 4: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Location x y \u2227 Resistance z \u2227 Trastuzumab z \u2227 Lead e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 ExtracellularDomain y \u2227 Target z \u2227 Agent e2 z \u2227 Patient e2 y \u2227 IntracellularDomain y \u2227 \u00acAffect e2\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the known information, we have HER2V777L x and Trastuzumab z. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab z\" <ATP>\\n  (* Using the logical relation Implies(C, E), we know that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it may cause resistance to antibody therapy. *)\\n  (* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\n  from explanation_2 have \"HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 LocatedIn x y \u2227 Trastuzumab z \u2227 \u00acTargetedBy x z\" <ATP>\\n  (* Therefore, we can infer that the HER2 V777L mutation may cause resistance to antibody therapy. *)\\n  then have \"Resistance y\" <ATP>\\n  (* Using the logical relation Implies(F, E), we know that if trastuzumab targets the extracellular domain and does not affect the intracellular domain, the HER2 V777L mutation may cause resistance to antibody therapy. *)\\n  (* Explanation 4 provides that trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\n  from explanation_4 have \"Trastuzumab z \u2227 ExtracellularDomain y \u2227 IntracellularDomain y \u2227 \u00acAffect e2\" <ATP>\\n  (* Therefore, we can infer that the HER2 V777L mutation may cause resistance to trastuzumab. *)\\n  then have \"Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z\" <ATP>\\n  (* We also know from explanation 1 that trastuzumab binds specifically to the HER2 extracellular domain. *)\\n  from explanation_1 have \"Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 Specifically e2\" <ATP>\\n  (* Combining all the information, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Mutations in the intracellular kinase domain are not affected by trastuzumab (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: The HER2 V777L mutation is not targeted by trastuzumab (from Explanatory Sentence 2)\\nE: The HER2 V777L mutation may cause resistance to antibody therapy (from Explanatory Sentence 3)\\nF: Trastuzumab targets the extracellular domain and does not affect the intracellular domain (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(F, E)\\nImplies(Trastuzumab targets the extracellular domain and does not affect the intracellular domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(F), B)\\nImplies(Not(Trastuzumab targets the extracellular domain and does not affect the intracellular domain), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(F))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab targets the extracellular domain and does not affect the intracellular domain))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, A)\\nImplies(Mutations in the intracellular kinase domain are not affected by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Mutations in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(E, A)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(F, A)\\nImplies(Trastuzumab targets the extracellular domain and does not affect the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(F))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab targets the extracellular domain and does not affect the intracellular domain))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), F)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab targets the extracellular domain and does not affect the intracellular domain)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(F, B)\\nImplies(Trastuzumab targets the extracellular domain and does not affect the intracellular domain, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(F), A)\\nImplies(Not(Trastuzumab targets the extracellular domain and does not affect the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), F)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab targets the extracellular domain and does not affect the intracellular domain)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, and this location can lead to resistance to antibody therapy. *)\\n(* Logical relation: Implies(C, D) and Implies(C, E) *)\\n(* We can infer that the HER2 V777L mutation is not targeted by trastuzumab and can lead to resistance. *)\\nthen have \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 IntracellularDomain x \u2227 \u00acTarget e2\" sledgehammer', 'solving time': 103.2644202709198, 'proof tactics': [], 'code': 'theory clinical_105_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Affect e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 \u00acAffect e2\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, and this location can lead to resistance to antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Located e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2 \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 x\"\\n\\n(* Explanation 3: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 IntracellularDomain z \u2227 Located e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 \u00acTarget e2\"\\n\\n(* Explanation 4: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Located e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Resistance z \u2227 Trastuzumab z \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 ExtracellularDomain z \u2227 Target e3 \u2227 Agent e3 z \u2227 Patient e3 y \u2227 \u00acAffect e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Resistance, and Trastuzumab. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z\" <ATP>\\n  (* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, and this location can lead to resistance to antibody therapy. *)\\n  (* Logical relation: Implies(C, D) and Implies(C, E) *)\\n  (* We can infer that the HER2 V777L mutation is not targeted by trastuzumab and can lead to resistance. *)\\n  then have \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 IntracellularDomain x \u2227 \u00acTarget e2\" <ATP>\\n  (* Explanation 4 states that the location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\n  (* Logical relation: Implies(C, H) and Implies(H, I) *)\\n  (* We can infer that the HER2 V777L mutation can lead to resistance to trastuzumab and trastuzumab targets the extracellular domain. *)\\n  then have \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Binding of trastuzumab does not affect mutations in the intracellular kinase domain (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: The HER2 V777L mutation is not targeted by trastuzumab (from Explanatory Sentence 2)\\nE: The HER2 V777L mutation can lead to resistance to antibody therapy (from Explanatory Sentence 2)\\nF: The HER2 V777L mutation may cause resistance to antibody therapy (from Explanatory Sentence 3)\\nG: Trastuzumab does not target the intracellular domain (from Explanatory Sentence 3)\\nH: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab (from Explanatory Sentence 4)\\nI: Trastuzumab targets the extracellular domain (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation can lead to resistance to antibody therapy)\\n--------\\nImplies(C, F)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(G, F)\\nImplies(Trastuzumab does not target the intracellular domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(C, H)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab)\\n--------\\nAnd(I, G)\\nG & I\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(D), G)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(B, I)\\nImplies(Binding of trastuzumab does not affect mutations in the intracellular kinase domain, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(H), G)\\nImplies(Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(E), I)\\nImplies(Not(The HER2 V777L mutation can lead to resistance to antibody therapy), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain))\\n--------\\nImplies(Not(F), F)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(I), Not(D))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(I), F)\\nImplies(Not(Trastuzumab targets the extracellular domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(G), G)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(G), F)\\nImplies(Not(Trastuzumab does not target the intracellular domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(A), Not(F))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(C), G)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(A, G)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(D), A)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, G)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(H, I)\\nImplies(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(H), A)\\nImplies(Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(E, G)\\nImplies(The HER2 V777L mutation can lead to resistance to antibody therapy, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(I), Not(F))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(F, G)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(A), G)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(H), B)\\nImplies(Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(B), I)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(The HER2 V777L mutation can lead to resistance to antibody therapy))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(G, A)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(F), B)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(D, A)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(F), G)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(G), B)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(E, A)\\nImplies(The HER2 V777L mutation can lead to resistance to antibody therapy, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(I), G)\\nImplies(Not(Trastuzumab targets the extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), The HER2 V777L mutation can lead to resistance to antibody therapy)\\n--------\\nImplies(G, B)\\nImplies(Trastuzumab does not target the intracellular domain, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(D), I)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(F, A)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(H), I)\\nImplies(Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(B, G)\\nImplies(Binding of trastuzumab does not affect mutations in the intracellular kinase domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(B, F)\\nImplies(Binding of trastuzumab does not affect mutations in the intracellular kinase domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(E, B)\\nImplies(The HER2 V777L mutation can lead to resistance to antibody therapy, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(Not(G), I)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(The HER2 V777L mutation can lead to resistance to antibody therapy))\\n--------\\nImplies(F, B)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(B), H)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab)\\n--------\\nImplies(Not(E), F)\\nImplies(Not(The HER2 V777L mutation can lead to resistance to antibody therapy), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(F), A)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(I), A)\\nImplies(Not(Trastuzumab targets the extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(C), I)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(G, I)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(I, F)\\nImplies(Trastuzumab targets the extracellular domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(A, I)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(B), Not(H))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab))\\n--------\\nImplies(Not(G), A)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, I)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(A), H)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab)\\n--------\\nImplies(E, I)\\nImplies(The HER2 V777L mutation can lead to resistance to antibody therapy, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(G), E)\\nImplies(Not(Trastuzumab does not target the intracellular domain), The HER2 V777L mutation can lead to resistance to antibody therapy)\\n--------\\nImplies(H, F)\\nImplies(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(I), B)\\nImplies(Not(Trastuzumab targets the extracellular domain), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(F, I)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(C, G)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(A), I)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation can lead to resistance to antibody therapy))\\n--------\\nImplies(Not(G), Not(F))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(F), H)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab)\\n--------\\nImplies(Not(I), H)\\nImplies(Not(Trastuzumab targets the extracellular domain), The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(B), Not(I))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(Trastuzumab targets the extracellular domain))\\n--------\\nImplies(Not(G), H)\\nImplies(Not(Trastuzumab does not target the intracellular domain), The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab)\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(G), Not(C))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(F), I)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(F), Not(E))\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Not(The HER2 V777L mutation can lead to resistance to antibody therapy))\\n--------\\nImplies(Not(E), B)\\nImplies(Not(The HER2 V777L mutation can lead to resistance to antibody therapy), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation can lead to resistance to antibody therapy)\\n--------\\nImplies(Not(I), I)\\nImplies(Not(Trastuzumab targets the extracellular domain), Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(I), Not(E))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(The HER2 V777L mutation can lead to resistance to antibody therapy))\\n--------\\nImplies(Not(B), Not(G))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(G), Not(H))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab))\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(E), G)\\nImplies(Not(The HER2 V777L mutation can lead to resistance to antibody therapy), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(I, G)\\nImplies(Trastuzumab targets the extracellular domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(A), Not(G))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(D), F)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(F), E)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), The HER2 V777L mutation can lead to resistance to antibody therapy)\\n--------\\nImplies(H, B)\\nImplies(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(I), E)\\nImplies(Not(Trastuzumab targets the extracellular domain), The HER2 V777L mutation can lead to resistance to antibody therapy)\\n--------\\nImplies(Not(H), F)\\nImplies(Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(F), D)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(F), Not(I))\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Not(Trastuzumab targets the extracellular domain))\\n--------\\nImplies(Not(I), D)\\nImplies(Not(Trastuzumab targets the extracellular domain), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(B), Not(F))\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(B, A)\\nImplies(Binding of trastuzumab does not affect mutations in the intracellular kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(F), C)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(H, G)\\nImplies(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(I), C)\\nImplies(Not(Trastuzumab targets the extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(A), Not(H))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab))\\n--------\\nImplies(Not(G), D)\\nImplies(Not(Trastuzumab does not target the intracellular domain), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(G), Not(I))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(Trastuzumab targets the extracellular domain))\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(I), Not(G))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(G), C)\\nImplies(Not(Trastuzumab does not target the intracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(E), A)\\nImplies(Not(The HER2 V777L mutation can lead to resistance to antibody therapy), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(Not(I), Not(A))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(I, A)\\nImplies(Trastuzumab targets the extracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(C), F)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(A, F)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(F), Not(B))\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain))\\n--------\\nImplies(Not(I), Not(C))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(I), Not(B))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain))\\n--------\\nImplies(D, F)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(B), G)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(F), Not(H))\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab))\\n--------\\nImplies(Not(B), F)\\nImplies(Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(I), Not(H))\\nImplies(Not(Trastuzumab targets the extracellular domain), Not(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab))\\n--------\\nImplies(C, I)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab targets the extracellular domain)\\n--------\\nImplies(Not(G), Not(B))\\nImplies(Not(Trastuzumab does not target the intracellular domain), Not(Binding of trastuzumab does not affect mutations in the intracellular kinase domain))\\n--------\\nImplies(E, F)\\nImplies(The HER2 V777L mutation can lead to resistance to antibody therapy, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(H, A)\\nImplies(The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(I, B)\\nImplies(Trastuzumab targets the extracellular domain, Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(A), Not(I))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab targets the extracellular domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Binding of trastuzumab does not affect mutations in the intracellular kinase domain)\\n--------\\nImplies(Not(A), F)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* Using Implies(C, D), we can infer that the HER2 V777L mutation is not targeted by trastuzumab. *)\\nthen have \"\u00acTargeted e1\" sledgehammer', 'solving time': 118.76054263114929, 'proof tactics': [], 'code': 'theory clinical_105_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  IntracellularTyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Targeted :: \"event \u21d2 bool\"  (* Added missing consts definition *)\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain z \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Affect e2 \u2227 \u00acAgent e2 x \u2227 Patient e2 y \u2227 Mutation y \u2227 IntracellularDomain y\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1. HER2V777L x \u2227 Mutation y \u2227 IntracellularTyrosineKinaseDomain z \u2227 Located e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 \u00acTargeted e1 \u2227 Agent e1 x\"\\n\\n(* Explanation 3: This specific location directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Location x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Lead e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 Target e2 \u2227 \u00acAgent e2 z \u2227 Patient e2 x \u2227 IntracellularDomain x\"\\n\\n(* Explanation 4: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation y \u2227 Resistance z \u2227 AntibodyTherapy z \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Located e2 \u2227 Agent e2 y \u2227 IntracellularDomain y \u2227 Target e2 \u2227 \u00acAgent e2 x \u2227 Patient e2 y\"\\n\\n(* Explanation 5: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3. Location x \u2227 HER2V777L y \u2227 Mutation y \u2227 IntracellularTyrosineKinaseDomain z \u2227 Resistance w \u2227 Trastuzumab w \u2227 Lead e1 \u2227 Agent e1 x \u2227 Patient e1 w \u2227 Target e2 \u2227 Agent e2 w \u2227 Patient e2 y \u2227 ExtracellularDomain y \u2227 Affect e3 \u2227 \u00acAgent e3 w \u2227 Patient e3 z \u2227 IntracellularDomain z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the known information, we have HER2V777L x, Resistance y, and Trastuzumab z. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z\" <ATP>\\n  (* Using Implies(C, E), we can infer Resistance y from HER2V777L x. *)\\n  then have \"Resistance y\" <ATP>\\n  (* Using Implies(C, D), we can infer that the HER2 V777L mutation is not targeted by trastuzumab. *)\\n  then have \"\u00acTargeted e1\" <ATP>\\n  (* Using And(A, B), we know that trastuzumab binds specifically to the HER2 extracellular domain, and mutations located in the intracellular kinase domain are not affected by trastuzumab. *)\\n  then have \"Bind e2 \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\" <ATP>\\n  (* Therefore, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Mutations located in the intracellular kinase domain are not affected by trastuzumab (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: The HER2 V777L mutation is not targeted by trastuzumab (from Explanatory Sentence 2)\\nE: Resistance to trastuzumab (from Explanatory Sentence 3)\\nF: Trastuzumab does not target the intracellular domain (from Explanatory Sentence 3)\\nG: Resistance to antibody therapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(F, E)\\nImplies(Trastuzumab does not target the intracellular domain, Resistance to trastuzumab)\\n--------\\nImplies(C, G)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to antibody therapy)\\n--------\\nImplies(F, G)\\nImplies(Trastuzumab does not target the intracellular domain, Resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), G)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Resistance to antibody therapy)\\n--------\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(A), Not(G))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Resistance to antibody therapy))\\n--------\\nImplies(Not(G), A)\\nImplies(Not(Resistance to antibody therapy), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(G, A)\\nImplies(Resistance to antibody therapy, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(F), B)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(F))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, A)\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(Not(G), B)\\nImplies(Not(Resistance to antibody therapy), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(E, A)\\nImplies(Resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(Resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Resistance to trastuzumab)\\n--------\\nImplies(G, B)\\nImplies(Resistance to antibody therapy, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(F, A)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(F))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(The HER2 V777L mutation is not targeted by trastuzumab, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is not targeted by trastuzumab))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), G)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Resistance to antibody therapy)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(Resistance to trastuzumab, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), F)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(Resistance to trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Resistance to trastuzumab)\\n--------\\nImplies(Not(B), Not(G))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Resistance to antibody therapy))\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is not targeted by trastuzumab)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(F, B)\\nImplies(Trastuzumab does not target the intracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(F), A)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(The HER2 V777L mutation is not targeted by trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), F)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* From D, we can infer that there is resistance. *)\\nthen have \"Resistance y\" sledgehammer', 'solving time': 133.81770157814026, 'proof tactics': [], 'code': 'theory clinical_105_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Affect e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 \u00acAffect e2\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Located e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2 \u2227 Resistance y\"\\n\\n(* Explanation 3: The specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Location z \u2227 Leads e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Resistance y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2\"\\n\\n(* Explanation 4: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 IntracellularDomain z \u2227 Located e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Trastuzumab z \u2227 Target e2 \u2227 \u00acTarget e2\"\\n\\n(* Explanation 5: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Location z \u2227 Lead e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Resistance y \u2227 Trastuzumab z \u2227 ExtracellularDomain z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 Affect e3 \u2227 Agent e3 z \u2227 Patient e3 y \u2227 \u00acAffect e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the known information, we have HER2V777L x and Trastuzumab z. *)\\n  from asm have \"HER2V777L x\" and \"Trastuzumab z\" <ATP>\\n  (* From HER2V777L x, we can infer C: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\n  then have \"The HER2 V777L mutation is located in the intracellular tyrosine kinase domain\" <ATP>\\n  (* Using Implies(C, D), we can infer D: The HER2 V777L mutation leads to resistance to trastuzumab. *)\\n  then have \"The HER2 V777L mutation leads to resistance to trastuzumab\" <ATP>\\n  (* From D, we can infer that there is resistance. *)\\n  then have \"Resistance y\" <ATP>\\n  (* From Trastuzumab z, we can infer A: Trastuzumab binds specifically to the HER2 extracellular domain. *)\\n  then have \"Trastuzumab binds specifically to the HER2 extracellular domain\" <ATP>\\n  (* Combine these inferences to construct the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Mutations in the intracellular kinase domain are not affected by trastuzumab (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: The HER2 V777L mutation leads to resistance to trastuzumab (from Explanatory Sentence 2)\\nE: Trastuzumab does not target the intracellular domain (from Explanatory Sentence 3)\\nF: Resistance to antibody therapy is caused by the HER2 V777L mutation (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation leads to resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(E, D)\\nImplies(Trastuzumab does not target the intracellular domain, The HER2 V777L mutation leads to resistance to trastuzumab)\\n--------\\nImplies(C, F)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to antibody therapy is caused by the HER2 V777L mutation)\\n--------\\nImplies(E, F)\\nImplies(Trastuzumab does not target the intracellular domain, Resistance to antibody therapy is caused by the HER2 V777L mutation)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation leads to resistance to trastuzumab))\\n--------\\nImplies(Not(F), B)\\nImplies(Not(Resistance to antibody therapy is caused by the HER2 V777L mutation), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(F))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(Resistance to antibody therapy is caused by the HER2 V777L mutation))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(The HER2 V777L mutation leads to resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, A)\\nImplies(Mutations in the intracellular kinase domain are not affected by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Mutations in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(E, A)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(F, A)\\nImplies(Resistance to antibody therapy is caused by the HER2 V777L mutation, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(F))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Resistance to antibody therapy is caused by the HER2 V777L mutation))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(The HER2 V777L mutation leads to resistance to trastuzumab, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation leads to resistance to trastuzumab)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation leads to resistance to trastuzumab))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(The HER2 V777L mutation leads to resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(Trastuzumab does not target the intracellular domain, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), F)\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Resistance to antibody therapy is caused by the HER2 V777L mutation)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation leads to resistance to trastuzumab)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(F, B)\\nImplies(Resistance to antibody therapy is caused by the HER2 V777L mutation, Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(F), A)\\nImplies(Not(Resistance to antibody therapy is caused by the HER2 V777L mutation), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Mutations in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(The HER2 V777L mutation leads to resistance to trastuzumab), Mutations in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), F)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Resistance to antibody therapy is caused by the HER2 V777L mutation)\\n--------\\n'}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* We have a logical relation Implies(C, E), which states that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it leads to resistance to trastuzumab. *)\\n(* From explanation 2, we know that HER2V777L x implies C, the mutation is located in the intracellular tyrosine kinase domain. *)\\nthen have \"Resistance y\" sledgehammer', 'solving time': 103.28074169158936, 'proof tactics': [], 'code': 'theory clinical_105_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  TyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Protein :: \"entity \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Effectively :: \"event \u21d2 bool\"\\n  Therapy :: \"entity \u21d2 bool\"\\n  Resulting :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Affect e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 \u00acAffect e2\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Located e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2 \u2227 Resistance y\"\\n\\n(* Explanation 3: The specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Location z \u2227 Leads e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Resistance y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2\"\\n\\n(* Explanation 4: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 IntracellularDomain z \u2227 Located e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 z \u2227 \u00acTarget e2\"\\n\\n(* Explanation 5: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Mutation x \u2227 IntracellularDomain y \u2227 TyrosineKinaseDomain y \u2227 Location z \u2227 Leads e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Resistance y \u2227 Trastuzumab z \u2227 ExtracellularDomain z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 z \u2227 Affect e3 \u2227 Agent e3 z \u2227 Patient e3 y \u2227 \u00acAffect e3\"\\n\\n(* Explanation 6: The HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Mutation x \u2227 Trastuzumab y \u2227 HER2 z \u2227 Protein z \u2227 Prevents e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Target e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 Effectively e2 \u2227 Resistance z \u2227 Therapy z \u2227 Resulting e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the known information, we have HER2V777L x and Trastuzumab z. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab z\" <ATP>\\n  (* We have a logical relation Implies(C, E), which states that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it leads to resistance to trastuzumab. *)\\n  (* From explanation 2, we know that HER2V777L x implies C, the mutation is located in the intracellular tyrosine kinase domain. *)\\n  then have \"Resistance y\" <ATP>\\n  (* We also have Implies(C, D), which states that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, and trastuzumab does not target the intracellular domain. *)\\n  (* From explanation 3, we know that trastuzumab does not target the intracellular domain, which implies D. *)\\n  then have \"Trastuzumab z \u2227 \u00acTarget e2\" <ATP>\\n  (* From explanation 1, we know that trastuzumab binds specifically to the HER2 extracellular domain, which implies A. *)\\n  then have \"Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x\" <ATP>\\n  (* Combining these, we can conclude that the HER2 V777L mutation may cause resistance to trastuzumab, as trastuzumab binds to the extracellular domain, whereas the mutation is in the intracellular domain. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Mutations located in the intracellular kinase domain are not affected by trastuzumab (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: Trastuzumab does not target the intracellular domain (from Explanatory Sentence 3)\\nE: Resistance to trastuzumab (from Explanatory Sentence 3)\\nF: The HER2 V777L mutation may cause resistance to antibody therapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(D, E)\\nImplies(Trastuzumab does not target the intracellular domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(C, F)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(F), B)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(F))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, A)\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(E, A)\\nImplies(Resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(Resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Resistance to trastuzumab)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(F, A)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(F))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation may cause resistance to antibody therapy))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(Trastuzumab does not target the intracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(Resistance to trastuzumab, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), F)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(Resistance to trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Resistance to trastuzumab)\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(F, B)\\nImplies(The HER2 V777L mutation may cause resistance to antibody therapy, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(F), A)\\nImplies(Not(The HER2 V777L mutation may cause resistance to antibody therapy), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(A), F)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation may cause resistance to antibody therapy)\\n--------\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* We have a logical relation Implies(C, E), which states that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it leads to resistance to trastuzumab. *)\\n(* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\nfrom explanation_2 have \"HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Resistance y\" sledgehammer', 'solving time': 103.41047835350037, 'proof tactics': [], 'code': 'theory clinical_105_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  IntracellularTyrosineKinaseDomain :: \"entity \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Location :: \"entity \u21d2 bool\"\\n  Specific :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Protein :: \"entity \u21d2 bool\"\\n  Effectively :: \"event \u21d2 bool\"\\n  Therapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain y \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Mutation z \u2227 IntracellularDomain z \u2227 Affect e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 \u00acAffect e2\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Located e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2 \u2227 Resistance y\"\\n\\n(* Explanation 3: The specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Location z \u2227 Specific z \u2227 In z y \u2227 Lead e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Resistance y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 \u00acTarget e2\"\\n\\n(* Explanation 4: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 Resistance y \u2227 AntibodyTherapy z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 IntracellularDomain x \u2227 Located e2 \u2227 Agent e2 x \u2227 Patient e2 x \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 \u00acTarget e2\"\\n\\n(* Explanation 5: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Location z \u2227 In z y \u2227 Lead e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Resistance y \u2227 Trastuzumab z \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 ExtracellularDomain y \u2227 Affect e3 \u2227 Agent e3 z \u2227 Patient e3 y \u2227 \u00acAffect e3\"\\n\\n(* Explanation 6: The HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation x \u2227 Trastuzumab y \u2227 HER2 z \u2227 Protein z \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Target e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 Effectively e2 \u2227 Resistance z \u2227 Therapy z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n  shows \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 Mutation x \u2227 IntracellularDomain x \u2227 In x z\"\\nproof -\\n  (* From the known information, we have HER2V777L x and Trastuzumab z. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab z\" <ATP>\\n  (* We have a logical relation Implies(C, E), which states that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it leads to resistance to trastuzumab. *)\\n  (* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)\\n  from explanation_2 have \"HER2V777L x \u2227 Mutation x \u2227 IntracellularTyrosineKinaseDomain y \u2227 Resistance y\" <ATP>\\n  (* Therefore, we can infer resistance to trastuzumab. *)\\n  then have \"Resistance y\" <ATP>\\n  (* Explanation 1 states that trastuzumab binds specifically to the HER2 extracellular domain. *)\\n  from explanation_1 have \"Trastuzumab z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x\" <ATP>\\n  (* Combining these, we can show the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Mutations located in the intracellular kinase domain are not affected by trastuzumab (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: Trastuzumab does not target the intracellular domain (from Explanatory Sentence 3)\\nE: Resistance to trastuzumab (from Explanatory Sentence 2, 3, 4, 5, 6)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(D, E)\\nImplies(Trastuzumab does not target the intracellular domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(A, Not(D))\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, Not(C))\\nImplies(Resistance to trastuzumab, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, Not(E))\\nImplies(Trastuzumab does not target the intracellular domain, Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, A)\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(C, Not(D))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(E, A)\\nImplies(Resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(Resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Resistance to trastuzumab)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(C, Not(A))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(Trastuzumab does not target the intracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(C, Not(C))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(B, Not(D))\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(D, C)\\nImplies(Trastuzumab does not target the intracellular domain, The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(D, Not(D))\\nImplies(Trastuzumab does not target the intracellular domain, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, Not(B))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(Resistance to trastuzumab, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(Resistance to trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(C, Not(E))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Resistance to trastuzumab)\\n--------\\nImplies(E, Not(D))\\nImplies(Resistance to trastuzumab, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(A, Not(C))\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, Not(C))\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, Not(C))\\nImplies(Trastuzumab does not target the intracellular domain, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(D, Not(B))\\nImplies(Trastuzumab does not target the intracellular domain, Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_105_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  HER2 :: \"entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  ExtracellularDomain :: \"entity \u21d2 bool\"\\n  IntracellularDomain :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Protein :: \"entity \u21d2 bool\"\\n  Therapy :: \"entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Affect :: \"event \u21d2 bool\"\\n  Located :: \"event \u21d2 bool\"\\n  Location :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Effectively :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3. Trastuzumab x \u2227 HER2 y \u2227 ExtracellularDomain z \u2227 Bind e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Specifically e1 \u2227 Affect e2 \u2227 \u00acAffect e2 \u2227 Mutation y \u2227 Located e3 \u2227 Agent e3 y \u2227 Patient e3 z \u2227 IntracellularDomain z\"\\n\\n(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation y \u2227 IntracellularDomain z \u2227 Located e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Target e2 \u2227 \u00acTarget e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Resistance y\"\\n\\n(* Explanation 3: The specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation y \u2227 IntracellularDomain z \u2227 Location e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Lead e2 \u2227 Directly e2 \u2227 Resistance y \u2227 Trastuzumab x \u2227 Target e2 \u2227 \u00acTarget e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 4: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation y \u2227 Resistance z \u2227 AntibodyTherapy z \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Located e2 \u2227 Agent e2 y \u2227 IntracellularDomain y \u2227 Target e2 \u2227 \u00acTarget e2 \u2227 Agent e2 x\"\\n\\n(* Explanation 5: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2 e3. HER2V777L x \u2227 Mutation y \u2227 IntracellularDomain z \u2227 Location e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Lead e2 \u2227 Resistance y \u2227 Trastuzumab x \u2227 Target e3 \u2227 Agent e3 x \u2227 ExtracellularDomain y \u2227 Affect e3 \u2227 \u00acAffect e3 \u2227 IntracellularDomain z\"\\n\\n(* Explanation 6: The HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mutation y \u2227 Trastuzumab z \u2227 Prevent e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Target e2 \u2227 Effectively e2 \u2227 HER2 y \u2227 Protein y \u2227 Result e2 \u2227 Resistance y \u2227 Therapy y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Trastuzumab z\"\\n  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)\\n  shows \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\"\\nproof -\\n  (* From the premise, we have the known information about HER2V777L and Trastuzumab. *)\\n  from asm have \"HER2V777L x \u2227 Trastuzumab z\" <ATP>\\n  (* The logical relation Implies(C, E) states that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain leads to resistance to trastuzumab. *)\\n  (* Since we have HER2V777L x, we can infer Resistance y. *)\\n  then have \"Resistance y\" <ATP>\\n  (* The logical relation Implies(C, D) states that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain implies trastuzumab does not target the intracellular domain. *)\\n  (* Since we have HER2V777L x, we can infer that trastuzumab does not target the intracellular domain. *)\\n  then have \"Trastuzumab does not target the intracellular domain\" <ATP>\\n  (* The logical relation Implies(A, Not(D)) states that trastuzumab binds specifically to the HER2 extracellular domain implies not trastuzumab does not target the intracellular domain. *)\\n  (* Since we have trastuzumab does not target the intracellular domain, we can infer trastuzumab binds specifically to the HER2 extracellular domain. *)\\n  then have \"Trastuzumab binds specifically to the HER2 extracellular domain\" <ATP>\\n  (* We can now construct the hypothesis using the derived information. *)\\n  then show \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 To y z \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 ExtracellularDomain x \u2227 IntracellularDomain x\" <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Trastuzumab binds specifically to the HER2 extracellular domain (from Explanatory Sentence 1)\\nB: Mutations located in the intracellular kinase domain are not affected by trastuzumab (from Explanatory Sentence 1)\\nC: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain (from Explanatory Sentence 2)\\nD: Trastuzumab does not target the intracellular domain (from Explanatory Sentence 3)\\nE: Resistance to trastuzumab (from Explanatory Sentence 2, 3, 4, 5, 6)\\n\\nLogical Relations:\\nAnd(A, B)\\nA & B\\n--------\\nImplies(C, D)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(D, E)\\nImplies(Trastuzumab does not target the intracellular domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(A, Not(D))\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\nImplies(C, E)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Resistance to trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, Not(C))\\nImplies(Resistance to trastuzumab, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, Not(E))\\nImplies(Trastuzumab does not target the intracellular domain, Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(B), Not(E))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(D, A)\\nImplies(Trastuzumab does not target the intracellular domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, B)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, A)\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(B), A)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(C, Not(D))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(E, A)\\nImplies(Resistance to trastuzumab, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(Not(A), Not(E))\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(Resistance to trastuzumab), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(A, B)\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Resistance to trastuzumab)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(C, Not(A))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), A)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, B)\\nImplies(Trastuzumab does not target the intracellular domain, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), B)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(C, Not(C))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(B, Not(D))\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(D, C)\\nImplies(Trastuzumab does not target the intracellular domain, The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(D, Not(D))\\nImplies(Trastuzumab does not target the intracellular domain, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(C, Not(B))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\nImplies(Not(B), C)\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), The HER2 V777L mutation is located in the intracellular tyrosine kinase domain)\\n--------\\nImplies(E, B)\\nImplies(Resistance to trastuzumab, Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(Resistance to trastuzumab), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(C, Not(E))\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Not(Resistance to trastuzumab))\\n--------\\nImplies(Not(A), E)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Resistance to trastuzumab)\\n--------\\nImplies(E, Not(D))\\nImplies(Resistance to trastuzumab, Not(Trastuzumab does not target the intracellular domain))\\n--------\\nImplies(Not(A), D)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Trastuzumab does not target the intracellular domain)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(Trastuzumab binds specifically to the HER2 extracellular domain))\\n--------\\nImplies(A, Not(C))\\nImplies(Trastuzumab binds specifically to the HER2 extracellular domain, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(A), B)\\nImplies(Not(Trastuzumab binds specifically to the HER2 extracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(B, Not(C))\\nImplies(Mutations located in the intracellular kinase domain are not affected by trastuzumab, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(C, A)\\nImplies(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, Trastuzumab binds specifically to the HER2 extracellular domain)\\n--------\\nImplies(D, Not(C))\\nImplies(Trastuzumab does not target the intracellular domain, Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab), Not(The HER2 V777L mutation is located in the intracellular tyrosine kinase domain))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(Trastuzumab does not target the intracellular domain), Mutations located in the intracellular kinase domain are not affected by trastuzumab)\\n--------\\nImplies(D, Not(B))\\nImplies(Trastuzumab does not target the intracellular domain, Not(Mutations located in the intracellular kinase domain are not affected by trastuzumab))\\n--------\\n'}"
        ]
    }
}